NNC172-2021

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Congenital Bleeding DisorderHaemophilia AHaemophilia BHealthy

Phase 1

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

CompletedNCT01555749

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A, Haemophilia B +1

Start: 2012-03-12End: 2012-05-08Updated: 2017-02-27

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

TerminatedNCT01631942

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A, Healthy

Start: 2012-06-26End: 2012-09-04Updated: 2019-05-15